Corporate Presentation Q4 2020 COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. Exhibit 99.1

This presentation includes forward-looking statements intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “continues,” “could,” “seeks,” “estimates,” “targets,” “guidance,” “expects,” “intends,” “may,” “ongoing,” “plans,” “potential,” “predicts,” “prospects,” “projects,” “should,” “will,” “would,” or similar expressions intended to identify statements about the future and the negatives of those terms, although not all forward-looking statements contain these identifying words. These statements are based on management’s current beliefs and expectations. These statements, including, but not limited to, statements regarding clinical utility tests, regulatory action, third-party payer reimbursement, and demand for our tests, are subject to substantial known and unknown risks, certainties, and other factors that could cause actual results to differ materially from those suggested or implied by these forward-looking statements. These factors include, but are not limited to, the following: regulatory action with respect to our existing and planned products (our “Products”); the commercial launch and future sales of our Products; our ability to achieve favorable pricing for our Products; third-party payor coverage and reimbursement for our Products and the impact of such coverage and reimbursement on our revenue growth; the accuracy of our estimates regarding anticipated capital requirements and our needs for additional financing; market size and market adoption of our Products by dermatologists and others; the timing, cost and other aspects of the commercial launch of our Products; the timing and cost of clinical utility tests for our Products, including whether such tests will be conducted at all; our ability to develop and commercialize additional tests and products; and our ability to enter into necessary transactions for licensing, acquisitions and strategic operations, as applicable. We may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on our forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from our current expectations are more fully described in our reports filed with the Securities and Exchange Commission (the “SEC”). You may obtain these reports for free by visiting EDGAR on the SEC website at www.sec.gov. We assume no obligation to update any forward-looking statements after the date of this presentation or to conform any forward-looking statements to actual results, and has no intention of doing so except to the extent required by applicable law. You should, therefore, not rely on the forward-looking statements in this presentation as representing our views as of any date subsequent to the date of this presentation. Disclaimer COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

Leadership Team Founder & Chairman, 10xBio (aesthetic medicine drugs) Chairman, Pantherics (anti-inflammatory drugs) MD, UCSD, Bachelors, UCLA Allergan, VP US Sales, Dermatology, Ophthalmology, Aesthetics Dexcom, VP Finance, Corporate Controller and Treasury, Interim CFO Biosite, FP&A, SEC Reporting, SOX Compliance MBA, MS, Kelley School of Business at Indiana University Senior roles at Nexogen, Advance, Celula, Nanogen Post-doctoral, UCSD PhD, Memorial University of Newfoundland Dermatologist FDA Consultant Post-doctoral, University of Minnesota; MD, University of Graz Exagen, Sr. VP Lab Operations Genoptix, Director Lab Operations Progenity, VP Payer Access OPKO/BRL, VP Managed Markets LabCorp Florida Blue, Kaiser, Carecentrix Immunologist Senior roles at Incyte, Medimmune Inventor IL-36 receptor antibody, Spesolimab Ph.D. West Virginia, thesis included use of tape stripping John Dobak, MD Chief Executive Officer Todd Wood Chief Comm. Officer Kevin Sun, MS, MBA Chief Financial Officer Zuxu Yao, PhD Chief Technology Officer Burkhard Jansen, MD Chief Medical Officer Claudia Ibarra Chief Operating Officer Daniel Visage, MBA Sr. VP, Payer Access Mike Howell, PhD Chief Scientific Officer COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. MISSION: To transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions

DermTech, Inc. (NASDAQ: DMTK) is a leader in precision dermatology enabled by a non-invasive skin genomics platform We address large market opportunities in skin disease with an initial focus in skin cancer We operate a CLIA-certified and CAP-accredited commercial laboratory in San Diego, CA. Our skin cancer product is available in all 50 U.S. states We are commercial stage and currently offer the Pigmented Lesion Assay (PLA) for early melanoma detection We are commencing scale up around our recent Medicare coverage policy and new CPT Code (0089U) with favorable reimbursement DermTech Mission: To transform dermatology with our non-invasive skin genomics platform. COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

Genomic Innovations Are Less Invasive, More Accurate, and Less Expensive Focus Company Old Standard of Care New-gen Diagnostic Breast Colorectal Thyroid Heart Lung Prenatal Skin COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

PLA Brings Skin Cancer Diagnostics into the 21st Century A Better Diagnostic Solution for Dermatology Subjective Visual Assessment Surgical Biopsy Subjective Histopathology Adhesive Patch Sample Collection Genomic Analysis CLIA/CAP Commercial Lab Physician Report (within 72 hrs.) Subjective Low Accuracy Invasive High Cost Objective High Accuracy Non-invasive Low Cost Current Practice: More Art Than Science The Future: Non-invasive Skin Genomics CAP: College of American Pathologists; CLIA: Clinical Laboratory Improvement Amendments. COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

More people are diagnosed with skin cancer than all other cancers combined and 1 in 5 Americans will develop skin cancer by the age of 70. More than 50 MM patients have UV related skin damage that puts them at risk for skin cancer Annual cost of treatment is estimated to be $8.1 billion, $4.8 billion for non-melanoma and $3.3 billion for melanoma (2018) ~4.5 million cases of basal cell and squamous cell diagnosed per year in the US, ~11 MM diagnostic biopsies, with ~20,000 deaths ~180,000 new cases of melanoma were reported in 2018, ~4.0 MM diagnostic biopsies, with ~10,000 deaths A Snapshot of the U.S. Skin Cancer Market ~3,000 new cases cutaneous lymphoma diagnosed, challenging diagnosis with average 3-6 years to definitive diagnosis, confusion with dermatitis leads to significant number of surgical biopsies (est. 420,000 annually) Skin Cancer Melanoma, Basal Cell, and Squamous Cell Carcinoma Source: Cancer Facts & Figures 2018. American Cancer Society. Source: AAD Skin Cancer Types Facts, aad.org Source: Cutaneous Lymphoma Foundation, clfoundation.org COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

DERMTECH’s Skin Cancer Product Pipeline Pigmented Lesion Assay (PLA) Melanoma R/O PLAplus Next Gen Melanoma R/O (Launch Postponed due to COVID Related Supply Chain Impacts) LuminateSM UV Damage and Skin Cancer Risk Carcinome Basal & Squamous Cell R/O CTCL Cutaneous T-cell Lymphoma R/O Product Discovery Stage Proof of Concept Stage Validation Stage Commercial Stage COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

PLA/PLAplusSM: melanoma1 skin cancer 4-4.5 MM diagnostic surgical biopsies Carcinome: non-melanoma skin cancer1 11-12 MM diagnostic surgical biopsies LuminateSM: UV damage and skin cancer risk2 82 MM U.S. Adults aged 35-54, ~1/3 actinic sun damage CTCL: Cutaneous lymphoma3 Estimated biopsies for inflammatory conditions that my be confused with CTCL ~400K-700K Skin Cancer Market Opportunity ~$10 BB Potential Procedure Volumes Potential U.S. Patient and Procedure Volumes 1. Source: IQVIA Skin Cancer Claims and Procedures Study 2. Source: Kaiser Family Foundation, kkf.org and DermTech Estimate 3. Source: DermTech KOL advisor estimates Estimated Total Potential Procedure Volumes and Market Opportunity Carcinome Luminate PLA CTCL COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

When Diagnosed at the Local Stage When Diagnosed at the Regional Stage When Diagnosed at the Distant Stage Not Skin Cancer Skin Cancer Not Skin Cancer Skin Cancer Early Detection of Melanoma Is Critical to Survival 5-Year Relative Survival Rate1 Early Detection Visually Is Extremely Difficult 98% 64% 23% 1. Cancer Facts & Figures 2018. American Cancer Society. 2. Hanke CW, Carcinoma and Keratoses, 1:2 2019 COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

~4.0-4.5 million biopsies annually to identify 180k cases Subjective Clinical Visual Assessment Most Biopsies Are NOT Melanoma Unmet Need: Melanoma’s Challenging Diagnostic Pathway Multiple biopsies and excisions of benign pigmented lesions. Courtesy of G. Peck, MD. 1. Anderson A, et al., JAMA Dermatology, 2018; doi:10.1001/jamadermatol.2018.0212 2. Elmore JG, et al. BMJ. 2017;357:j2813. 3. Strazzula L, et al. Journal of the American Academy of Dermatology, 2014; 71:1071-6 COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. Diagnostic Inaccuracy and Unnecessary Surgery Leads to ~25 surgical biopsies performed per melanoma found1 Assess only 1% of the Lesion 58% of early-stage melanomas have diagnostic misinterpretation2 Leads to high proportion (>20%) unnecessary wide excisions3 Subjective Pathology Assessment

The First Non-invasive Gene Expression and Mutation Test to Enhance Melanoma Detection COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. 1. Data on File. DermTech, Inc. 2. Jackson RJ, Jansen B, Yao Z, Ferris LK. Skin. 2020;4(2):105-110 3. Gerami P, Yao Z, Polsky D, et al. J Am Acad Dermatol. 2017;76(1):114-120. 4. Jansen B, et al. J Drugs Dermatol. 2018;17(5):574-576. Non-invasive Adhesive Patches Avoids unnecessary surgery1,2  Improves patient care and comfort Earliest Detection Detects genomic drivers of cancer1,3,4 Genomic changes can precede visual changes1,3,4 Highly Accurate Reduces probability of missing melanoma (<1%) 100% of a lesion is sampled Uses the precision of genomics

Better Care at a Lower Cost Performance Metric Biopsy & Histology PLA Test Improvement Probability of Missed Melanoma1 17% 1% 17x Biopsies per Melanoma2 25 2.7 10x Wide Excisions per Melanoma2,3 5.2 1.6 3x Cost per Lesion Tested4 ~$1,000 $760 $240 Fewer biopsies while missing fewer melanomas A long-term follow-up confirms the high NPV and high utility of the PLA in helping guide the management of pigmented lesions5 Highly Validated with Proven Clinical Utility Enhance early detection of melanoma by identifying lesions with genomic atypia 1. Elmore JG, et al. BMJ. 2017; 357:j2813 & Malvehy J, et al. BJD, 2014; 177:1099-1107 2. Ferris L, et al. JAMA Dermatol, 2018; 154(10):1229-1230 & Gerami P, et al., JAAD 2017, 76:114-120e 3. Strazzula L, et al. JAAD, 2014; 71:1071-6 & Ferris L, et al. Melanoma Research, 2018 1:DOI10.1097 4. Hornberger J and Siegel D. JAMA Dermatol, 2018 154(9):1-8 5. Ferris L, et al. DOJ, 2019, 25(5)1-8 6. Ferris LK, Moy RL, Gerami P et al. J Invest Dermatol. 2019;139(5):1127-1134 COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. Highly Validated Diagnostic Metrics sensitivity2,6 91%-97% negative predictive value (NPV) vs 83% NPV of current pathway1,2 >99% of cases2,5 98% Clinicians follow the guidance of the test in over Validated in 14 peer reviewed publications Superior Performance

Strong Clinical Validation and Robust IP Portfolio Milestone Status Sample Size Analytical Validation ✔ Complete 125 Clinical Validation – pathology ✔ Complete 555 Clinical Validation – mutation ✔ Complete 626 Clinical Utility ✔ Complete 45 Derms Real-World Utility ✔ Complete 381 1-Year Follow-up ✔ Complete 734 Real-World Utility Registry ✔ Complete 3418 Adhesive Biopsy Validation ✔ Complete N/A Health Economic ✔ Complete 326 CPT Codes ✔ Complete N/A Issued US patents provide broad protection for melanoma product through 2030 Broad methods covering RNA analysis of adhesive patch collected skin: 7,183,057 Method of detection of biological factors in epidermis: 6,720,145 Broad claims for melanoma gene classifier: 9,057,109 Broad claims for melanoma gene classifier: 10,407,729 IP Portfolio CPT: Current Procedural Terminology; N/A: not applicable. Publications available at www.dermtech.com Patents issued in select countries worldwide Multiple European countries, Canada, Japan, and Australia Trade secrets and technical know-how Low quantity, poor quality sample material requires special processes Custom automation COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

CMS Pricing in Place Unlocks Significant Market Opportunity ~2.0 Million Total Biopsies2 ~$1.5 Billion $760 Reimbursement2 ~2.0 Million Total Biopsies Reimbursement TBD Expect in-line with Medicare payment rate +$1 Billion (est.) Medicare Other Medicare Market Alone Has Potential for >$1 Billion in Sales 1. Source: IQVIA Skin Cancer Claims and Procedures Study 2020 Clinical Laboratory Fee Schedule: https://www.cms.gov/medicaremedicare-fee-service-paymentclinicallabfeeschedclinical-laboratory-fee-schedule-files/20clabq1 COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. Medicare Coverage Established in January 2020 Estimated Total Number U.S. Biopsies for Pigmented Lesions1 Medicare1 Commercial Payors1

DermTech’s Goal: Eliminate Melanoma Deaths in the US There are 5 Requirements to Eradicate a Disease Diagnostic test with 99% NPV & is agreeable with patients Treatment protocol with 99% efficacy Payer model to fund effective diagnosis & treatment Widespread HCP adoption of diagnostic pathway & treatment protocol Activated consumers willing to be evaluated Current Pathway Does Not Meet Requirements Invasive biopsy & pathology with 83% NPV & unpopular with patients 99% 5-year survival rate when detected early Biopsy & pathology widely covered Diagnosis restricted to dermatology Very few patients visit dermatology

PLA Case Study – JAMA Dermatology Publication 28-year-old female Family history of melanoma Complained of bug bite Refused surgical biopsy PLA test was positive Histopathology revealed 0.5-mm melanoma Curative wide excision performed Case study published in JAMA Dermatology1 Effectiveness Attributes of the PLA Test 1. Childs MV. JAMA Dermatol, 2018, 154(2):223 Background DermTech Results COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

Commercial Activities COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

Commercial Channels Telemedicine Integrated Primary Care Networks On- and near-site employer health clinics & retail clinics Social Media Paid Search Programmatic Display Direct sales reps Inside sales reps Regional managers Medical science liaisons Dermatology Professional Channel Digital Consumer Channel Future Care Delivery Channel COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

Dermatology Professional Sales Force Each circle represents a prioritized dermatology target: high number melanoma biopsies, >50% proportion Medicare patients 45-50 sales reps give coverage of 13,000 dermatology clinical professionals ~80% sales manger hiring complete ~5,000 prioritized targets Average ~66 biopsies/mo/clinician Drive to average of 10 PLA tests/mo/clinician2 Based on historical physician productivity metrics Minimal impact to biopsy practice ~10% served market penetration = ~446,000 tests per year Revenue potential @ 10% penetration = ~$312 MM/year3 1. Source: IQVIA Skin Cancer Claims and Procedures Study 2. DermTech estimate based on historical “good” account 3. Assumes convergence of Medicare and commercial payer rates with average ASP of $700/test U.S. Field Sales Territory Map = Target HCP Color = Sales territory COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

Digital Consumer Channel is Driving Awareness and Patients to Take Action Source: Socialbakers; Google Analytics​; Acuity, May-Oct, 2020, select U.S. regions Data: Includes metrics across both published (organic and boosted) and unpublished content on owned social platforms​ The DermTech PLA | Early Detection of Melanoma | Pain-Free Adhesive Patch www.dermtech.com Introducing The DermTech PLA. A Transformative, Pain-Free Way to Detect Melanoma. Adhesive Patch That Detects The Genes Found in Melanoma. Learn More Today. 59.3M Total Impressions 2.4M Social Engagements 452K Clicks 51k Derm Searches COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

Store & Forward iPhone and Android App Secure email and text HCP network of users Remote interactive access Sent to patient’s home Supported by easy to use instructions QR Code activates instructional video Employer service providers Benefit providers Integrated networks Other Telemedicine channels including skin disease Future Cancer Care Dx Delivered via Telemedicine Channel COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. Telemedicine Technology Solution Patient Home Collection Kit Potential Partnerships With Existing Real-Time Interactive Providers

Ordering Clinician Installed Based and Sample Volume Resumed Growth Post Q2 COVID Shutdown Trained Sales Reps: ~7 Trained Sales Reps: ~23 Trained Sales Reps: ~7 Trained Sales Reps: ~7 Trained Sales Reps: ~23 Trained Sales Reps: ~33 COVID-19 QTR Source: DermTech, Inc. Training program for new sales reps is 3 months COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. DermTech Historical Quarterly Billable Sample Volume and Ordering Clinicians

Beginning to Monetize Sample Volume With Recent Medicare Coverage DermTech Historical Quarterly Assay Revenue and ASP Trained Sales Reps: ~7 Trained Sales Reps: ~23 Trained Sales Reps: ~7 Trained Sales Reps: ~7 Trained Sales Reps: ~23 Trained Sales Reps: ~33 Source: DermTech, Inc., Capital IQ, Bloomberg Training program for new sales reps is 3 months COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. COVID-19 QTR Commercial Payer Coverage Expected To Further Accelerate Revenue Growth* *Recently contracted with BCBS of IL and BS of CA with early 2021 effective dates.

Commercial Lab Operations CLIA-licensed laboratory in State of California and all states requiring out-of-state licensure CAP-accredited ~9000-square-foot commercial lab space Current floorspace capacity of 300,000 tests per year PLA/PLAplus assay turnaround time is ~3-4 days COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

Impact Discussion We are deemed an essential business and our commercial laboratory remains fully operational Dermatology offices have not yet re-opened to full capacity and future operations are dependent upon regional COVID-19 infection rates and regional restrictions We have been conducting virtual sales calls, providing client education, and introduced a telemedicine option for remote, clinician-guided sample collection We completed approximately 80% of our sales force expansion for the year by July 2020 and expect to finish 2020 with ~40 sales representatives We cannot predict which states will remain open, but we did recently see some encouraging data which underscores clinician acceptance of the DermTech PLA including: Sample volume recovery in October 2020 to all time high levels Sample volume for September and October 2020 increased 34%, compared to January and February 2020 In October 2020, we had an all-time high in the number of ordering clinicians who order 10 or more tests per month. COVID-19 COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

Back Up COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

THE PLAplus: Optimized Gene Targets Novel marker discovered by DermTech Member of a rapidly growing family of regulatory RNA molecules Important regulator of oncogenesis - play role in melanoma proliferation and invasion Overexpressed in melanoma Well described target involved in many tumors, including in melanoma progression and metastasis Independently validated- Haqq, Myriad, Castle Promotes tumor progression by interfering with retinoic acid receptor signaling Overexpressed in melanoma Involved in many tumors, is found in 70-80% of melanoma Mutations lead to oncogenesis through functional increases in TERT protein, telomerase activity, telomere length, cell immortalization and proliferation Associated with histopathologic features of aggressiveness and poor survival in melanoma Increased Sensitivity to 97% COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. 1. Lessard L, Liu M, Marzese et al. J Invest Dermatol. 2015;135(10):2464-74. 2. Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME. Epigenetics. 2015;10(2):103-21. 3. Ikeda H, Lethé B, Lehmann F et al. Immunity. 1997;6(2):199-208. 4. Hermes N, Kewitz S, Staege MS. Curr Cancer Drug Targets. 2016;16(5):400-414.  5. Ferris LK, Moy RL, Gerami P et al. J Invest Dermatol. 2019;139(5):1127-1134 6. Nagore E, Rachakonda S, Kumar R. Oncotarget. 2019;10(16):1546-1548 LINC005181,2 Long Intergenic Non-Coding RNA 518 PRAME3,4 Preferentially Expressed Antigen in Melanoma TERT5,6 Telomerase Reverse Transcriptase Promoter

Quantifies UV damage to the genome in normal appearing skin by assessing driver mutations for basal cell and squamous cell cancer Identifies risk for skin cancer and premature photoaging Generates UV Damage score Non-sun exposed areas of skin from the buttocks have zero score Patients with a history of skin cancer have highest score Informs patients about actions and treatments that can be undertaken to repair damage and improve skin health Consumer Health Offering Outliers relative to age can be identified Mutations accumulated with age; outliers relative to peers identified Age UV Damage Score Source: DermTech data Mutation Burden Increases with Sun Exposure COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. UV Exposure:

~$12 million in research programs booked to date Robust pipeline of opportunities and pending contracts Independent performance development Expansion to late-stage trials (phase ll, lll) Research Partnerships and Collaborations Indication* Pilot Phase 1 Phase 2 Phase 3 Pemphigus Vulgaris Hidradenitis Suppurative Psoriasis Mantle Cell Lymphoma Follicular Lymphoma Lupus Vitiligo Atopic Dermatitis Chronic Spontaneous Urticaria COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

Improved Practice Efficiency & Patient Capacity Ambiguous lesions photographed & followed-up Most atypical/obvious lesion Patient with Multiple Pigmented Lesions Physician Billing Higher E&M Coding 1 Surgical Biopsy PLA Define PLA Positioning and Clarify Practice Economics The PLA Provides Comparable Economics With Better Patient Care 1. Based on AMA billing criteria for CPT E&M codes 2. Net economics accounting for differences in cost for labor (physician work vs. nursing work) and supplies 3. Biopsy procedure costs based on AMA RVS Update Committee figures 4. Reimbursement rates based on Medicare payments for established patient E&M CPT codes and biopsy procedure CPT codes, CodeMapTM COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. Physician Billing Biopsy Procedure Code 11300 Comparable Practice Economics2,3,4

Precision Dermatology Delivers More Accurate Melanoma Detection Samples 100% of lesion Provides additional objective genomic information Measures malignant changes that cannot be seen visually Samples less than 1%-2% of a potentially partial surgical biopsy Relies on subjective visual criteria Morphologic changes must be present and in the field of observation PLA Dermatopathology RNA and DNA collected by the PLA/PLAplus spans across the entire lesion1,2 Significant improvement against current standard of care COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. RNA=ribonucleic acid; RT-PCR=reverse transcription polymerase chain reaction. 1. Ferris LK, et al. JAMA Dermatol. 2017;153(7):675-680. 2. Data on File. DermTech, Inc.